| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | 0.076 | 0.6 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | 0.08 | 0.6 |